Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2018-05-26 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1" and is explicitly labeled as a "Company Announcement." It details decisions regarding clinical trials (termination/discontinuation) based on DMC recommendations and subsequent actions by Janssen. This type of announcement, which communicates significant operational or clinical development news to the market, fits best under the general category of regulatory or company updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a specific legal filing, and it is a direct announcement of company activity, it falls under the broad 'Regulatory Filings' (RNS) category, which serves as a catch-all for important, non-standardized corporate disclosures. Given the length and content, it is not a simple Report Publication Announcement (RPA).
2018-05-26 English
Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the termination of clinical studies for a drug (daratumumab). It provides details on the clinical trial status, the reasons for termination (lack of benefit/safety concerns), and the impact on the partnership with Janssen. While it discusses clinical trial results, it is not a full audit report or a quarterly financial report. It is a specific corporate announcement regarding operational/clinical developments. According to the 'Menu vs Meal' rule, although it mentions an attachment, the text itself is a substantive announcement of a material event, fitting the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2018-05-26 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a formal announcement titled "Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin's Lymphoma." It details the outcome of a clinical trial, specifically stating that the primary endpoint was not met. This content—announcing key results from clinical studies, often preceding a full scientific publication or inclusion in a larger report—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it focuses purely on the immediate financial/operational impact of a clinical trial result (topline data) rather than being a comprehensive quarterly/annual report (10-K or IR), the Earnings Release (ER) category is the most appropriate fit for immediate market-moving news. It is not a transcript (CT), a full annual report (10-K), or a general regulatory filing (RNS), but a specific operational/financial result announcement.
2018-05-24 English
Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma
Regulatory Filings Classification · 95% confidence The document is a company announcement from Genmab regarding the topline results of a Phase III clinical trial. It provides a summary of the trial outcome, the company's perspective, and background information on the drug and the study. While it discusses clinical trial results, it does not constitute a full financial report or a regulatory filing of a specific form type. It is a standard corporate press release/announcement. Given the 'Menu vs Meal' rule and the nature of the content, it fits best as a general regulatory announcement or corporate news release, which falls under the RNS category in this schema.
2018-05-24 English
Director's Dealing 2018
Director's Dealing Classification · 99% confidence The document is a formal template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a specific transaction (Sale of shares) by a Board member (Anders Gersel Pedersen) of the issuer (Genmab A/S) on a specific date (2018-05-17). This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by executives and directors.
2018-05-18 English
Director's Dealing 2018
Director's Dealing Classification · 99% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details transactions (specifically 'Sale of shares') conducted by individuals holding positions like 'Member of the Board of Directors' and 'President & Chief Executive Officer' of the issuer (Genmab A/S). This content directly corresponds to the reporting requirements for insider trading or director's dealings. Among the provided codes, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for reports detailing personal share transactions by company directors and executives.
2018-05-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.